Medicare AdvantageCoverageMedium impact
MA08.049q, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.049q for Paclitaxel Protein-Bound Particles (Abraxane) has been updated with an effective date of October 1, 2025. This policy change affects the coverage and billing requirements for this injectable cancer medication used primarily in oncology treatments.
Action Required
By October 1, 2025: Billing team should review the complete policy MA08.049q for Paclitaxel Protein-Bound Particles (Abraxane) to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for Medicare Advantage patients. Contact the payer or access the full policy document to determine specific billing modifications needed.